Hematologic safety of 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer.
Groener D, Nguyen CT, Baumgarten J, Bockisch B, Davis K, Happel C, Mader N, Nguyen Ngoc C, Wichert J, Banek S, Mandel P, Chun FKH, Tselis N, Grünwald F, Sabet A.
Groener D, et al. Among authors: mandel p.
EJNMMI Res. 2021 Jul 3;11(1):61. doi: 10.1186/s13550-021-00805-7.
EJNMMI Res. 2021.
PMID: 34216290
Free PMC article.